European Archives of Oto-Rhino-Laryngology

, Volume 272, Issue 7, pp 1755–1762 | Cite as

Human papilloma virus and survival of oropharyngeal cancer patients treated with surgery and adjuvant radiotherapy

  • Martina A. Broglie
  • Alex Soltermann
  • Sarah R. Haile
  • Gerhard F. Huber
  • Sandro J. Stoeckli
Head and Neck


Impact of p16 protein, a surrogate marker for human papilloma virus induced cancer, p53 and EGFR as well as clinical factors on survival in a patient cohort with oropharyngeal squamous cell carcinoma (OPSCC) treated by surgical resection and adjuvant radiotherapy (RT) ± concomitant chemotherapy (CT). This is a retrospective analysis of patient’s charts and tumor tissue. 57 patients were consecutively included and their tumor tissue assembled on a tissue microarray following immunohistochemical analysis. Survival times were estimated by means of Kaplan–Meier analysis. The importance of clinical and immunohistochemical factors for outcome was estimated by cox proportional hazard models. With 88 % 5-year overall survival, 91 % 5-year disease-specific survival and 91 % 5-year disease-free survival, respectively, we found excellent survival rates in this surgically treated patient cohort of mainly advanced OPSCC (93 % AJCC stage III or IV). The only factors positively influencing survival were p16 overexpression as well as p53 negativity and even more pronounced the combination of those biomarkers. Survival analysis of patients classified into three risk categories according to an algorithm based on p16, smoking, T- and N-category revealed a low, intermediate and high-risk group with significant survival differences between the low and the high-risk group. Patients with OPSCC can be successfully treated by surgery and adjuvant RT ± CT with a clear survival benefit of p16 positive, p53 negative patients. We recommend considering a combination of immunohistochemical (p16, p53) and clinical factors (smoking, T- and N-category) for risk stratification.


Oropharyngeal cancer Surgery Survival Human papillomavirus p16 p53 


Conflict of interest

There are no financial disclosures or conflicts of interest.


  1. 1.
    Tschudi D, Stoeckli S, Schmid S (2003) Quality of life after different treatment modalities for carcinoma of the oropharynx. Laryngoscopes 113(11):1949–1954CrossRefGoogle Scholar
  2. 2.
    Broglie MA, Soltermann A, Haile SR, Roosli C, Huber GF, Schmid S et al (2013) Quality of life of oropharyngeal cancer patients with respect to treatment strategy and p16-positivity. Laryngoscope 123(1):164–170Google Scholar
  3. 3.
    Gillison ML (2006) Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers. J Clin Oncol 24(36):5623–5625CrossRefPubMedGoogle Scholar
  4. 4.
    Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P et al (2001) Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 344(15):1125–1131CrossRefPubMedGoogle Scholar
  5. 5.
    Olthof NC, Straetmans JM, Snoeck R, Ramaekers FC, Kremer B, Speel EJ (2012) Next-generation treatment strategies for human papillomavirus-related head and neck squamous cell carcinoma: where do we go? Rev Med Virol 22(2):88–105CrossRefPubMedGoogle Scholar
  6. 6.
    Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100(4):261–269CrossRefPubMedGoogle Scholar
  7. 7.
    Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM (2001) Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 92(4):805–813CrossRefPubMedGoogle Scholar
  9. 9.
    Lindquist D, Romanitan M, Hammarstedt L, Nasman A, Dahlstrand H, Lindholm J et al (2007) Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol 1(3):350–355CrossRefPubMedGoogle Scholar
  10. 10.
    Butz K, Geisen C, Ullmann A, Spitkovsky D, Hoppe-Seyler F (1996) Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. Int J Cancer 68(4):506–513CrossRefPubMedGoogle Scholar
  11. 11.
    Bristow RG, Benchimol S, Hill RP (1996) The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol 40(3):197–223CrossRefPubMedGoogle Scholar
  12. 12.
    Haughey BH, Hinni ML, Salassa JR, Hayden RE, Grant DG, Rich JT et al (2011) Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck 33(12):1683–1694CrossRefPubMedGoogle Scholar
  13. 13.
    Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R et al (2006) High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24(36):5630–5636CrossRefPubMedGoogle Scholar
  14. 14.
    Fischer CA, Zlobec I, Green E, Probst S, Storck C, Lugli A et al (2010) Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer 126(5):1256–1262PubMedGoogle Scholar
  15. 15.
    Cohen MA, Weinstein GS, O’Malley BW Jr, Feldman M, Quon H (2011) Transoral robotic surgery and human papillomavirus status: oncologic results. Head Neck 33(4):573–580CrossRefPubMedGoogle Scholar
  16. 16.
    Broglie MA, Tinguely M, Holzman D (2009) How to diagnose sinus fungus balls in the paranasal sinus? An analysis of an institution’s cases from January 1999 to December 2006. Rhinology 47(4):379–384PubMedGoogle Scholar
  17. 17.
    Roosli C, Tschudi DC, Studer G, Braun J, Stoeckli SJ (2009) Outcome of patients after treatment for a squamous cell carcinoma of the oropharynx. Laryngoscope 119(3):534–540CrossRefPubMedGoogle Scholar
  18. 18.
    Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952CrossRefPubMedGoogle Scholar
  19. 19.
    Studer G, Huguenin PU, Davis JB, Kunz G, Lutolf UM, Glanzmann C (2006) IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients. Radiat Oncol 1:7CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Studer G, Furrer K, Davis BJ, Stoeckli SS, Zwahlen RA, Luetolf UM et al (2006) Postoperative IMRT in head and neck cancer. Radiat Oncol 1:40CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Ragin CC, Taioli E (2007) Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 121(8):1813–1820CrossRefPubMedGoogle Scholar
  22. 22.
    Mehta V, Yu GP, Schantz SP (2010) Population-based analysis of oral and oropharyngeal carcinoma: changing trends of histopathologic differentiation, survival and patient demographics. Laryngoscope 120(11):2203–2212CrossRefPubMedGoogle Scholar
  23. 23.
    Ernster JA, Sciotto CG, O’Brien MM, Finch JL, Robinson LJ, Willson T et al (2007) Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope 117(12):2115–2128CrossRefPubMedGoogle Scholar
  24. 24.
    Smith EM, Wang D, Rubenstein LM, Morris WA, Turek LP, Haugen TH (2008) Association between p53 and human papillomavirus in head and neck cancer survival. Cancer Epidemiol Biomarkers Prev 17(2):421–427CrossRefPubMedGoogle Scholar
  25. 25.
    Mellin H, Dahlgren L, Munck-Wikland E, Lindholm J, Rabbani H, Kalantari M et al (2002) Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer 102(2):152–158CrossRefPubMedGoogle Scholar
  26. 26.
    Hafkamp HC, Manni JJ, Haesevoets A, Voogd AC, Schepers M, Bot FJ et al (2008) Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 122(12):2656–2664CrossRefPubMedGoogle Scholar
  27. 27.
    Maxwell JH, Kumar B, Feng FY, Worden FP, Lee JS, Eisbruch A et al (2010) Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 16(4):1226–1235CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH et al (2008) EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26(19):3128–3137CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Jakobsen J, Hansen O, Jorgensen KE, Bastholt L (1998) Lymph node metastases from laryngeal and pharyngeal carcinomas–calculation of burden of metastasis and its impact on prognosis. Acta Oncol 37(5):489–493CrossRefPubMedGoogle Scholar
  30. 30.
    Straetmans JM, Olthof N, Mooren JJ, de Jong J, Speel EJ, Kremer B (2009) Human papillomavirus reduces the prognostic value of nodal involvement in tonsillar squamous cell carcinomas. Laryngoscope 119(10):1951–1957CrossRefPubMedGoogle Scholar
  31. 31.
    Dahlstrom KR, Calzada G, Hanby JD, Garden AS, Glisson BS, Li G et al (2013) An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair. Cancer 119(1):81–89Google Scholar
  32. 32.
    Moore EJ, Olsen SM, Laborde RR, Garcia JJ, Walsh FJ, Price DL et al (2012) Long-term functional and oncologic results of transoral robotic surgery for oropharyngeal squamous cell carcinoma. Mayo Clin Proc 87(3):219–225CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Park YM, Kim WS, Byeon HK, Lee SY, Kim SH (2013) Oncological and functional outcomes of transoral robotic surgery for oropharyngeal cancer. Br J Oral Maxillofac Surg 51(5):408–412Google Scholar
  34. 34.
    Al-Mamgani A, Van Rooij P, Tans L, Teguh DN, Levendag PC (2013) Toxicity and Outcome of Intensity-Modulated Radiotherapy versus 3-Dimensional Conformal Radiotherapy for Oropharyngeal Cancer: a Matched-Pair Analysis. Technol Cancer Res Treat 12(2):123–130Google Scholar
  35. 35.
    Lok BH, Setton J, Caria N, Romanyshyn J, Wolden SL, Zelefsky MJ et al (2012) Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes. Int J Radiat Oncol Biol Phys 82(5):1851–1857CrossRefPubMedGoogle Scholar
  36. 36.
    Daly ME, Le QT, Maxim PG, Loo BW Jr, Kaplan MJ, Fischbein NJ et al (2010) Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 76(5):1339–1346CrossRefPubMedGoogle Scholar
  37. 37.
    Hodge CW, Bentzen SM, Wong G, Palazzi-Churas KL, Wiederholt PA, Gondi V et al (2007) Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? An inter-era comparison. Int J Radiat Oncol Biol Phys 69(4):1032–1041CrossRefPubMedGoogle Scholar
  38. 38.
    Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J et al (2006) Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24(5):736–747CrossRefPubMedGoogle Scholar
  39. 39.
    Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Snijders PJ, Pawlita M et al (2007) A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 121(11):2465–2472CrossRefPubMedGoogle Scholar
  40. 40.
    Reimers N, Kasper HU, Weissenborn SJ, Stutzer H, Preuss SF, Hoffmann TK et al (2007) Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 120(8):1731–1738CrossRefPubMedGoogle Scholar
  41. 41.
    Hoffmann M, Tribius S, Quabius ES, Henry H, Pfannenschmidt S, Burkhardt C et al (2012) HPV DNA, E6*I-mRNA expression and p16INK4A immunohistochemistry in head and neck cancer—how valid is p16INK4A as surrogate marker? Cancer Lett 323(1):88–96CrossRefPubMedGoogle Scholar
  42. 42.
    Rietbergen MM, Snijders PJ, Beekzada D, Braakhuis BJ, Brink A, Heideman DA et al (2014) Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas. Int J Cancer 134(10):2366–2372CrossRefPubMedGoogle Scholar
  43. 43.
    Ukpo OC, Flanagan JJ, Ma XJ, Luo Y, Thorstad WL, Lewis JS (2011) High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol 35(9):1343–1350CrossRefPubMedGoogle Scholar
  44. 44.
    Holzinger D, Flechtenmacher C, Henfling N, Kaden I, Grabe N, Lahrmann B et al (2013) Identification of oropharyngeal squamous cell carcinomas with active HPV16 involvement by immunohistochemical analysis of the retinoblastoma protein pathway. Int J Cancer 133(6):1389–1399CrossRefPubMedGoogle Scholar
  45. 45.
    Lindel K, Rieken S, Daffinger S, Weber KJ, de Villiers EM, Debus J (2012) The transcriptional regulator gene E2 of the human papillomavirus (HPV) 16 influences the radiosensitivity of cervical keratinocytes. Radiat Oncol 7(1):187CrossRefPubMedCentralPubMedGoogle Scholar
  46. 46.
    Pang E, Delic NC, Hong A, Zhang M, Rose BR, Lyons JG (2011) Radiosensitization of oropharyngeal squamous cell carcinoma cells by human papillomavirus 16 oncoprotein E6 *I. Int J Radiat Oncol Biol Phys 79(3):860–865CrossRefPubMedGoogle Scholar
  47. 47.
    Mehra R, Ang KK, Burtness B (2012) Management of human papillomavirus-positive and human papillomavirus-negative head and neck cancer. Semin Radiat Oncol 22(3):194–197CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Martina A. Broglie
    • 1
  • Alex Soltermann
    • 2
  • Sarah R. Haile
    • 3
  • Gerhard F. Huber
    • 4
  • Sandro J. Stoeckli
    • 1
  1. 1.Department of Otorhinolaryngology, Head and Neck SurgeryKantonsspital St. GallenSt. GallenSwitzerland
  2. 2.Institute of Surgical PathologyUniversity Hospital of ZurichZurichSwitzerland
  3. 3.Clinical Trials UnitKantonsspital St. GallenSt. GallenSwitzerland
  4. 4.Department of Otorhinolaryngology, Head and Neck SurgeryUniversity Hospital of ZurichZurichSwitzerland

Personalised recommendations